Ventiv's Clinical Services division has joined with India's largest
domestic contract research organization (CRO), SIRO Clinpharm, to
provide India-based clinical data management services, offering
pharma and biotech companies...
UK-based Synexus Clinical Research has formed the first
patient-recruitment site management organisation (SMO) in India to
cash in on India's burgeoning clinical research market.
BioGenetics Capital announced that it has closed a $5.5 million
financing round with Contract Research Organisation (CRO) Services
Group, Clinquest Group, in a move that gives the company access to
the fast-growing life sciences markets...
India's clinical research industry is currently valued at $100
million (€83 million) and is almost doubling each year, reflecting
the shifting focus of the pharmaceutical outsourcing industry to
Asia.
Omnicare will soon be offering staff that are "eClinical trained"
as a strategic tool to woo clinical trial contracts and compete
with services offered by rival contract research organizations
(CROs) such as Quintiles.
Covalent Group has improved its financial position on last year,
reporting a net revenue increase of 45 per cent for the third
quarter of 2005 with sales of $2.7 million, (€2.3 million) compared
to $1.9 million one year ago.
Contract research organisations (CROs) are responding to the
looming threat of competition from India and China by moving
outside their traditional role of simply providing contract
services to drug companies.
Accelovance has broadened its presence in China and expanded its
capacity for conducting Phase I-IV clinical trials for Western
pharmaceutical and biotech firms seeking to enter the Chinese
market, by opening a new office in Shanghai.
Generex has escalated manufacturing capabilities to meet expected
demand for the first ever commercially available non-injectable
insulin product, to be launched in Ecuador at the end of the month.
Pain Therapeutics and King Pharmaceuticals have entered into an
alliance to develop and commercialise Remoxy in an alliance worth
at least $400 million (€342 million). The deal positions the
abuse-resistant opioid painkiller as a...
German biotech company Evotec OAI boosted its third quarter
revenues by 18 per cent to €19 million, despite the difficult
operating environment for companies supplying drug discovery
technologies, continuing its recovery from a weak...
A Phase I clinical trial, which is investigating the
pharmacological activities of a compound for the treatment of
Alzheimer's disease, has just been completed with results
indicating improved efficacy and pharmacokinetics over...
Penn Pharmaceutical Services has reported strong sales figures for
the fifth consecutive year, with a key driver of recent growth
being attributed to a boom in contract manufacturing as well as
small-scale commercial batches.
Research Dynamics have struck a deal with VirtualScopics in which
they have signed a non-exclusive partnership agreement to co-market
their clinical research services and technologies.
Australian drug delivery company pSivida has inked a deal valued at
$104 million (€87m) to buy Control Delivery Systems of the US,
allowing it tap into the biotechnology hub around Boston on the US
east coast.
Contract biopharmaceutical manufacturer SynCo Bio Partners has
started construction of two new manufacturing suites at its
facility in Amsterdam, the Netherlands, in a move that builds on
the firm's ability to make microbial...
GlaxoSmithKline has halted clinical trials of its first-in-class
HIV drug after cases of hepatotoxicity was discovered in
treatment-naïve patients. The setback does not mean the end of
development for this drug candidate but suggests...
Scientists in research and academia have called for the end to the
pharmaceutical industry's 'cynical use' of drug studies and its
subjects who are often misled into taking part.
Pharmos has announced the initiation of a phase I trial with
cannabinor, a CB2-selective synthetic cannabinoid drug candidate.
The trial aims to assess the drug's potential as a treatment for
neuropathic, inflammatory, visceral,...
The creation of Sanofi-Aventis last year created a dent in its
second-quarter net profit as the French company looked to provide
good news to its investors. The drug maker managed to raise its
earnings target for the year and accelerated...
Increasing adoption of computational biology tools in today's drug
discovery is the industry's attempt to compensate for shrinking
product pipelines as the industry also expects to reduce the
duration of the drug discovery...
Vioxx. Bextra. Zyprexa, Seroxat. At no period of time have so many
high-profile drugs come under the spotlight as drug companies face
legal action over drug safety. It's make or break time for the
pharmaceutical industry as drug...
Pharmaceutical outsourcing firm Quintiles Transnational Corp is
selling three of its business units, covering preclinical services,
pharmaceutical sciences and clinical trial supplies, to newly
formed company Aptuit.
Who's making what for whom? In-PharmaTechnologist provides its
periodic round-up of new deals and developments in the
pharmaceutical contract manufacturing sector.
Biovitrum and Santhera have announced the signing of an exclusive
license and collaboration agreement, which aims to develop DPP-IV
inhibitors for the treatment of type 2 diabetes and other metabolic
diseases.
Santhera Pharmaceuticals and the Takeda Pharmaceutical Company have
established a collaboration to develop and market the first
treatment for Friedreich's Ataxia - a genetic condition that
impacts quality of life substantially...
Diosynth Biotechnology, the contract manufacturing subsidiary of
Dutch chemicals and pharmaceuticals group Akzo Nobel, has won a new
contract to manufacture a cardiovascular imaging agent due to start
Phase III testing in 2006.
The raft of pharmaceutical companies reporting results for the
second quarter of 2005 provided mixed indications as to the state
of the industry. The claim that pipeline product fruition is
beginning to return among the pharmaceutical...
According to latest findings, the biotechnology/pharmaceutical
industry submitted 542 commercial Investigational New Drug (IND)
applications in 2004, increasing by more than a third from the
previous year.
A recent report has identified the need for effective clinical
investigator recruitment, which has become so crucial in the
laboratory management of successful clinical trials and subsequent
product launches.
Bayer Healthcare has announced that it will publish information
about its ongoing clinical trials, reinforcing the intention of the
pharmaceutical companies within the industry to provide an arena in
which they can publish information...
Biopharmaceutical company, deCODE genetics, has provided an update
on its lead clinical and preclinical drug development pipeline,
emphasising the role human genetics is playing in broadening its
preclinical portfolio in areas of...
Editors of eleven international medical journals have amplified
their call for the registration of drug trials before the first
patient is enrolled,in a medium that is fully searchable and
publicly accessible at no charge.
A former editor of the British Medical Journal (BMJ) claims that
medical journals are an extension of the marketing arm of
pharmaceutical companies, placing editors in difficult positions as
company-funded trials are becoming increasingly...
The contract manufacturing sector lagged behind the rest of the
outsourcing industry serving the pharmaceutical sector in 2004, but
there are encouraging signs for the future, reports Phil
Taylor.
Bentley Pharmaceuticals has entered into an agreement with Dong
Sung Pharmaceuticals for the development of an intranasal spray
formulation of insulin for the South Korean market with the view of
extending this deal into additional...
An electronic nebuliser that matches a product formulation, which
was specifically developed to optimise this device's performance,
marks a new advance in the customisation of drug development and
represents a new aerosol delivery...
SkyePharma will shortly sign up a marketing partner for its
improved formulation of the local anaesthetic bupivacaine, a
product which the UK-based drug delivery company says is one of the
most important products in its pipeline.
According to a new report diabetic nephropathy represents a
multi-billion-dollar market that is poorly served by existing
drugs. All this is set to change as Palosuran, currently in
clinical development, could become the first drug...
The decreasing number of truly original drugs approved by the Food
and Drug Administration is becoming such a serious issue that the
pharmaceutical market's tag as the 'innovator industry' is being
called into question,...
China and India are forecasted as the most exciting prospects for
European pharmaceutical and biotechnology companies. Despite having
over a third of the world's population, Asia accounts for only one
fifth of global pharmaceutical...
A new potential diabetes drug from Dia-B Tech, which is based on a
naturally occurring peptide consisting of four amino acids,
promises convenience and fewer side effects over current day
treatments for type 2 diabetes.
Construction of the UK National Biomanufacturing Centre, an
ambitious project aimed at helping biotechnology start-ups get
their product ideas into clinical trials, is progressing on
schedule and should be ready to start production...
A report out today cites Novartis' pipeline of drugs to continue
its reputation of producing quality pharmaceuticals, with
treatments for cancer, age-related macular degeneration and
hypertension expected to appear within the...
In response to accusations of a cover up over negative data and
placing patient safety at risk, pharmaceutical companies worldwide
have agreed to reveal the results of clinical trial drug data.
Merck & Co, still reeling from the impact of pulling its
painkiller Vioxx (rofecoxib) from the market, is to slash its staff
by 5,100 positions in a bid to save hundreds of millions of dollars
by the end of the year.
